Compare RCI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCI | JAZZ |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 16.1B |
| IPO Year | 2002 | 2007 |
| Metric | RCI | JAZZ |
|---|---|---|
| Price | $33.22 | $242.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 22 |
| Target Price | $37.54 | ★ $296.77 |
| AVG Volume (30 Days) | ★ 1.2M | 745.1K |
| Earning Date | 10-23-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $4.17 | $12.57 |
| Revenue Next Year | $1.01 | $5.14 |
| P/E Ratio | ★ $4.12 | $6,059.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.26 | $156.95 |
| 52 Week High | $41.14 | $266.38 |
| Indicator | RCI | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 61.88 |
| Support Level | $31.64 | $236.70 |
| Resistance Level | $35.21 | $250.49 |
| Average True Range (ATR) | 0.88 | 7.34 |
| MACD | 0.07 | 3.76 |
| Stochastic Oscillator | 58.19 | 84.08 |
Rogers Communications is one of Canada's "Big 3" telecom service providers, offering wireless and broadband services nationally, but with strongholds in Ontario, British Columbia, and Alberta. The firm serves 11 million postpaid and 1 million prepaid wireless customers and 5 million broadband customers with nearly 11 million homes passed. Rogers also operates a media segment, primarily known for ownership of three major Toronto sports teams: baseball's Blue Jays, hockey's Maple Leafs, and basketball's Raptors. Additionally, the firm operates multiple broadcast networks, radio stations, and public venues in the Rogers Centre.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.